Mirja Harms

840 total citations
25 papers, 349 citations indexed

About

Mirja Harms is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Mirja Harms has authored 25 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 10 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Mirja Harms's work include Chemokine receptors and signaling (9 papers), Immunotherapy and Immune Responses (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Mirja Harms is often cited by papers focused on Chemokine receptors and signaling (9 papers), Immunotherapy and Immune Responses (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Mirja Harms collaborates with scholars based in Germany, Denmark and United States. Mirja Harms's co-authors include Jan Münch, Elsa Sánchez‐García, Yasser B. Ruiz‐Blanco, Janis A. Müller, Ludger Ständker, Michael Ehrmann, Joel Mieres‐Pérez, Annika Röcker, Andrea Gilg and Benjamin Mayer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Journal of Virology.

In The Last Decade

Mirja Harms

24 papers receiving 349 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mirja Harms Germany 11 172 65 58 58 48 25 349
Yoan Machado Canada 13 210 1.2× 119 1.8× 29 0.5× 46 0.8× 53 1.1× 21 459
San Sui Lim Australia 10 83 0.5× 107 1.6× 32 0.6× 45 0.8× 12 0.3× 14 285
Cecilia Carnrot Sweden 9 177 1.0× 55 0.8× 39 0.7× 61 1.1× 51 1.1× 10 325
Vashti Irani Australia 6 150 0.9× 117 1.8× 24 0.4× 39 0.7× 132 2.8× 7 328
Adrien Lugari France 9 242 1.4× 53 0.8× 21 0.4× 180 3.1× 30 0.6× 13 463
Rudo Simeon United States 9 154 0.9× 60 0.9× 36 0.6× 87 1.5× 98 2.0× 12 354
Hung‐Pin Peng Taiwan 15 403 2.3× 87 1.3× 45 0.8× 48 0.8× 257 5.4× 27 614
Arjen Companjen Netherlands 14 215 1.3× 274 4.2× 38 0.7× 38 0.7× 30 0.6× 24 497
Rina Fong United States 7 426 2.5× 93 1.4× 118 2.0× 112 1.9× 73 1.5× 8 649
Rebecca A. Buonpane United States 10 144 0.8× 158 2.4× 41 0.7× 121 2.1× 108 2.3× 11 370

Countries citing papers authored by Mirja Harms

Since Specialization
Citations

This map shows the geographic impact of Mirja Harms's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mirja Harms with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mirja Harms more than expected).

Fields of papers citing papers by Mirja Harms

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mirja Harms. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mirja Harms. The network helps show where Mirja Harms may publish in the future.

Co-authorship network of co-authors of Mirja Harms

This figure shows the co-authorship network connecting the top 25 collaborators of Mirja Harms. A scholar is included among the top collaborators of Mirja Harms based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mirja Harms. Mirja Harms is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gaonkar, Raghuvir H., Thèodorine Bailly, Jacopo Millul, et al.. (2025). Improving Affinity while Reducing Kidney Uptake of CXCR4‐Targeting Radioligands Derived from the Endogenous Antagonist EPI‐X4. ChemMedChem. 20(6). e202400773–e202400773. 1 indexed citations
3.
Rodríguez, Armando, Ludger Ständker, Mirja Harms, et al.. (2024). An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR–ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences. 25(15). 8306–8306. 2 indexed citations
4.
Rodríguez, Armando, Zhixuan Zhou, Thomas Monecke, et al.. (2024). A naturally occurring 22-amino acid fragment of human hemoglobin A inhibits autophagy and HIV-1. Cellular and Molecular Life Sciences. 81(1). 409–409. 2 indexed citations
5.
Harms, Mirja, Andrea Gilg, Jessica Löffler, et al.. (2023). Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability. Journal of Medicinal Chemistry. 66(22). 15189–15204. 6 indexed citations
6.
Gaonkar, Raghuvir H., Rosalba Mansi, Elsa Sánchez‐García, et al.. (2023). Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications. Journal of Medicinal Chemistry. 66(13). 8484–8497. 5 indexed citations
7.
Harms, Mirja, Rüdiger Groß, Benjamin Mayer, et al.. (2022). Utilization of Aminoguanidine Prevents Cytotoxic Effects of Semen. International Journal of Molecular Sciences. 23(15). 8563–8563. 1 indexed citations
8.
Ruiz‐Blanco, Yasser B., Joel Mieres‐Pérez, Mirja Harms, et al.. (2022). PPI-Affinity: A Web Tool for the Prediction and Optimization of Protein–Peptide and Protein–Protein Binding Affinity. Journal of Proteome Research. 21(8). 1829–1841. 49 indexed citations
9.
10.
Harms, Mirja, Manuel Hayn, Fabian Zech, Frank Kirchhoff, & Jan Münch. (2022). Endogenous Peptide Inhibitors of HIV Entry. Advances in experimental medicine and biology. 1366. 65–85. 1 indexed citations
11.
Rodríguez, Armando, Andrea Gilg, Ludger Ständker, et al.. (2022). Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability. International Journal of Molecular Sciences. 23(23). 15029–15029. 8 indexed citations
12.
Hayn, Manuel, Armando Rodríguez, Solange Vidal, et al.. (2021). Natural cystatin C fragments inhibit GPR15-mediated HIV and SIV infection without interfering with GPR15L signaling. Proceedings of the National Academy of Sciences. 118(3). 12 indexed citations
13.
Sokkar, Pandian, Mirja Harms, Christina M. Stürzel, et al.. (2021). Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists. Communications Biology. 4(1). 1113–1113. 20 indexed citations
14.
Gilg, Andrea, et al.. (2021). Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations. Journal of Translational Medicine. 19(1). 190–190. 2 indexed citations
15.
Harms, Mirja, Andrea Gilg, Ludger Ständker, et al.. (2020). Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands. Scientific Reports. 10(1). 16 indexed citations
16.
Harms, Mirja, Andrea Gilg, Nico Preising, et al.. (2020). An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation. Acta Pharmaceutica Sinica B. 11(9). 2694–2708. 32 indexed citations
17.
Kaiser, Lisa, Mirja Harms, Jan Münch, & Christian Buske. (2020). CXCR4 Signaling in AML Is Dampened By the Endogenous CXCR4 Inhibitory Peptide EPI-X4. Blood. 136(Supplement 1). 22–22. 2 indexed citations
18.
Conzelmann, Carina, Min Zou, Rüdiger Groß, et al.. (2019). Storage-Dependent Generation of Potent Anti-ZIKV Activity in Human Breast Milk. Viruses. 11(7). 591–591. 24 indexed citations
19.
Frich, Camilla Kaas, Annika Röcker, Janis A. Müller, et al.. (2017). Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses. Advanced Healthcare Materials. 6(23). 47 indexed citations
20.
Harms, Mirja, Franziska Franke, & Peter Klein. (2012). Der Henndorfer Truhenfund : Dokumentation und Datierung von 127 gefassten siebenbürgischen Truhen des 15. bis 18. Jahrhunderts. 1. 150. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoan Machado Breakdown of academic impact, for papers by San Sui Lim Breakdown of academic impact, for papers by Cecilia Carnrot Breakdown of academic impact, for papers by Vashti Irani Breakdown of academic impact, for papers by Adrien Lugari Breakdown of academic impact, for papers by Rudo Simeon Breakdown of academic impact, for papers by Hung‐Pin Peng Breakdown of academic impact, for papers by Arjen Companjen Breakdown of academic impact, for papers by Rina Fong Breakdown of academic impact, for papers by Rebecca A. Buonpane
Rankless by CCL
2026